Maria G. Crespo-Leiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria G. Crespo-Leiro has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
A Castro-Beiras
Instituto Universitario Ciencias de la Salud, Universidad de A Coruña (M.H.-P., J.M., S.B., A.C.-B.), A Coruña, Spain
3 shared publicationsA Juffé
Programa de Trasplante Cardiaco, Hospital Juan Canalejo (M.G.C.-L., J.A.R., M.J.P., L.F.H., A.J.), A Coruña, Spain
2 shared publicationsA. Castro-Beiras
2 shared publicationsB. Diaz-Molina
H Central de Asturias, Oviedo, Spain
2 shared publicationsC. Naya
2 shared publicationsE. Lage
H Virgen del Rocio, Sevilla, Spain
2 shared publications
Latest Publications
- 1 November 2008
- Published by Elsevier in Transplantation Proceedings
- Vol. 40 (9) , 3060-3062
The Efficacy and Safety of Ezetimibe for Treatment of Dyslipidemia After Heart Transplantation
- 1 November 2008
- Published by Elsevier in Transplantation Proceedings
- Vol. 40 (9) , 3060-3062
The Efficacy and Safety of Ezetimibe for Treatment of Dyslipidemia After Heart Transplantation
- Open Access
- 30 May 2008
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 29 (22) , 2703-2704
Sirolimus treatment of left ventricular hypertrophy: who, and when?
The protein known as mammalian target of rapamycin (mTOR) plays vital roles in protein synthesis, and hence in growth and cell proliferation, including the proliferation of immune response cells and neoplastic cells. The paths through which it acts have two main branches that start from mTOR complexes known as mTORC1/RAPTOR and mTORC2/RICTOR. The former is inhibited by sirolimus (rapamycin), everolimus, and their analogues, while the latter is not. Despite not inhibiting mTORC2/RICTOR, the sirolimus family are known collectively as mTOR inhibitors, and also as proliferation signal inhibitors (PSIs).1
- 30 May 2008
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 29 (22) , 2703-2704
Open AccessSirolimus treatment of left ventricular hypertrophy: who, and when?
The protein known as mammalian target of rapamycin (mTOR) plays vital roles in protein synthesis, and hence in growth and cell proliferation, including the proliferation of immune response cells and neoplastic cells. The paths through which it acts have two main branches that start from mTOR complexes known as mTORC1/RAPTOR and mTORC2/RICTOR. The former is inhibited by sirolimus (rapamycin), everolimus, and their analogues, while the latter is not. Despite not inhibiting mTORC2/RICTOR, the sirolimus family are known collectively as mTOR inhibitors, and also as proliferation signal inhibitors (PSIs).1
- Open Access
- 30 May 2008
- Published by Elsevier in American Journal of Transplantation
- Vol. 8 (6) , 1336-1339
Reversal of Cardiac Cirrhosis Following Orthotopic Heart Transplantation
- 30 May 2008
- Published by Elsevier in American Journal of Transplantation
- Vol. 8 (6) , 1336-1339
Open AccessReversal of Cardiac Cirrhosis Following Orthotopic Heart Transplantation
- Open Access
- 14 April 2008
- Published by Elsevier in American Journal of Transplantation
- Vol. 8 (5) , 1031-1039
Malignancy After Heart Transplantation: Incidence, Prognosis and Risk Factors
- 14 April 2008
- Published by Elsevier in American Journal of Transplantation
- Vol. 8 (5) , 1031-1039
Open AccessMalignancy After Heart Transplantation: Incidence, Prognosis and Risk Factors
- Open Access
- 1 February 2002
- Published by Elsevier in Transplantation Proceedings
- Vol. 34 (1) , 161-163
Microchimerism after heart transplantation: prevalence, predisposing factors, natural history, and prognosis
- 1 February 2002
- Published by Elsevier in Transplantation Proceedings
- Vol. 34 (1) , 161-163
Open AccessMicrochimerism after heart transplantation: prevalence, predisposing factors, natural history, and prognosis
- 1 February 1999
- Vol. 18 (2) , 172
Cardiac troponin T is not a marker of biopsy-proven cellular rejection.
- 1 February 1999
- Vol. 18 (2) , 172
Cardiac troponin T is not a marker of biopsy-proven cellular rejection.
- 1 April 1998
- Vol. 39 (2) , 217-9
Chylous ascites following heart transplantation.
We report a case of chylous ascites in a 52-year-old woman after an orthotopic heart transplantation. The patient was successfully managed with conservative treatment including dietetic measures and repeated paracentesis. The potential aetiopathological factors involved and other implications for cardiac transplant patients are discussed.
- 1 April 1998
- Vol. 39 (2) , 217-9
Chylous ascites following heart transplantation.
We report a case of chylous ascites in a 52-year-old woman after an orthotopic heart transplantation. The patient was successfully managed with conservative treatment including dietetic measures and repeated paracentesis. The potential aetiopathological factors involved and other implications for cardiac transplant patients are discussed.